Urinary concentration of a specific peptide of type I collagen of bone (CrossLaps<sup>TM</sup>): correlation to hydroxyproline

Silsand, Terje; Reine, Andreas; Dugal, S.; Lunde, T.; Smedsrud, B.; Seeberg, T.

doi:10.3109/00365519509089612

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike the cumbersome measurement of pyridinoline, deoxypyridinoline and hydroxyproline by HPLC [18], CrossLaps ELISA is an assay for routine and simple clinical use. CrossLaps can therefore be recommended as a sensitive and convenient biochemical marker of bone resorption.…”

Section: Discussionmentioning

confidence: 99%

“…Urinary levels of pyridinoline, deoxypyridinoline and hydroxyproline were measured by high pressure liquid chromatography (HPLC). Urinary CrossLaps levels were measured with an ELISA kit (Osteometer, Copenhagen, Denmark) and a monoclonal antibody directed against an immobilized synthetic peptide with an amino acid sequence specific for a part of the Ctelopeptide of the ui-chain of type I collagen (Glu-Lys-Ala-His-Asp-Gly-Gly-Arg = CrossLaps peptide) [17,18]. The intra-and interassay coefficients of variation of the test were 2.3% and 4.6%, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…Urinary CrossLaps is derived specifically from a degradation product of type I collagen of bone and has been shown to be a sensitive and specific marker of bone resorption [9,17,18]. A monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) has been developed to measure urinary excretion of CrossLaps [17,18]. Early postmenopausal women have been shown to exhibit increased CrossLaps levels [17].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical Usefulness of Urinary CrossLaps as a Sensitive Marker of Bone Metabolism.

et al. 1997

View full text Add to dashboard Cite

CrossLaps peptide [Glu-Lys-Ala-His-Asp-Gly-Gly-Arg], a part of the C-telopeptide of the alpha 1-chain of type I collagen of bone, is a recently developed biochemical marker of bone turnover. In this study, the clinical utility of measurement of urinary CrossLaps was investigated in eleven premenopausal women who received a gonadotropin-releasing hormone (GnRH) agonist for 6 months for treatment of adenomyosis (n = 1) or leiomyomas (n = 10). Along with urinary CrossLaps, the levels of various biochemical markers, and serum estradiol, calcitonin and intact parathyroid hormone (i-PTH) were measured, and lumbar spine bone mineral density (BMD) was also monitored before, during, and at the end of the course of GnRH agonist therapy. Apart from CrossLaps, markers of bone resorption tested were urinary pyridinoline, deoxypyridinoline and hydroxyproline. Markers of bone formation tested were serum osteocalcin and bone-specific alkaline phosphatase (B-ALP). Serum estradiol levels decreased to undetectable levels at 2 months of GnRH agonist therapy. The values for all biochemical markers increased significantly throughout the therapy. The degree of an increase in CrossLaps levels was greater than that in all other markers. Mean lumbar spine (L2-L4) BMD was decreased by 7.2% at 6 months of treatment. The percent change in BMD at 6 months of treatment correlated inversely with the percent change in CrossLaps levels from the baseline to 1, 2, and 5 months of treatment. These results indicate that measurement of urinary CrossLaps might be a useful tool to predict the risk of bone loss caused by hypoestrogenism including GnRH agonist therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical Usefulness of Urinary CrossLaps as a Sensitive Marker of Bone Metabolism.

et al. 1997

View full text Add to dashboard Cite

show abstract

“…(a) The urinary excretion values of CrossLaps™ correlate with those of hydroxyproline (which is an established marker of bone resorption) (134).…”

Section: Diagnostic Validitymentioning

confidence: 99%

Review

1996

CCLM

View full text Add to dashboard Cite

A review is given summarizing the present knowledge of bone turnover markers with special emphasis on biological, preanalytical and technical criteria in the proper judgement of efficacy and limitations of the methods employed. The marker substances may be either measures of bone formation or bone resorption.Markers of bone formation are bone alkaline phosphatase, osteocalcin and the carboxyl-terminal propeptide of procollagen type I. Bone alkaline phosphatase has proved to be superior to total alkaline phosphatase activity with respect to diagnostic sensitivity and specificity. Immunochemical techniques for measuring bone alkaline phosphatase show a cross-reactivity of 14-20% with liver alkaline phosphatase. However, this does not compromise the clinical usefulness of these assays except for patients with severe liver diseases. Osteocalcin is strictly bone-specific but shows numerous disadvantages with respect to apparent instability and discordant results as obtained by different methods; however, in certain diagnostic situations (corticosteroid-induced osteopenia, absence of destroyed bone architecture) osteocalcin may serve as a sensitive bone turnover marker. The carboxyl-terminal propeptide of procollagen type I generally shows low discriminating power in the diagnosis of bone diseases.The urinary excretion of pyridinium 'cross-links' has been carefully evaluated so far with respect to analytical performance and clinical usefulness. This marker may be a substitute for 4-hydroxyproline measurements as the method of choice for assessment of bone resorption. There are other degradation products from the telopeptide regions of bone-derived collagen type I which are excreted into the urine (N-telopeptides, CrossLaps™)\ these analytes are promising tools in the assessment of bone resorption but require further evaluation, in particular with respect to their extraskeletal clearance and putative origin outside bone. Moreover, their clinical usefulness may vary depending on the patient group examined. In contrast, the serum concentration of the cross-linked telopeptide region of collagen type I seems to lack both diagnostic specificity and sensitivity in the majority of patient groups. Tartrate-resistant acid phosphatase (as determined by the presently available methods) cannot be recommended as a routine tool for assessment of bone resorption.Brought to you by | University of Arizona Authenticated Download Date | 7/8/15 5:47 AM

show abstract

Monitoring collagen degradation in patients with arthritis. The search for suitable surrogates

Greenwald

1996

Arthritis & Rheumatism

View full text Add to dashboard Cite

Urinary concentration of a specific peptide of type I collagen of bone (CrossLaps^TM): correlation to hydroxyproline

Cited by 6 publications

References 17 publications

Clinical Usefulness of Urinary CrossLaps as a Sensitive Marker of Bone Metabolism.

Clinical Usefulness of Urinary CrossLaps as a Sensitive Marker of Bone Metabolism.

Review

Monitoring collagen degradation in patients with arthritis. The search for suitable surrogates

Contact Info

Product

Resources

About

Urinary concentration of a specific peptide of type I collagen of bone (CrossLapsTM): correlation to hydroxyproline

Cited by 6 publications

References 17 publications

Clinical Usefulness of Urinary CrossLaps as a Sensitive Marker of Bone Metabolism.

Clinical Usefulness of Urinary CrossLaps as a Sensitive Marker of Bone Metabolism.

Review

Monitoring collagen degradation in patients with arthritis. The search for suitable surrogates

Contact Info

Product

Resources

About

Urinary concentration of a specific peptide of type I collagen of bone (CrossLaps^TM): correlation to hydroxyproline